{ "schemaVersion": "deck-intelligence.v1", "id": "019de515-1bf5-75fc-a19f-ef7a3323e229", "slug": "a43786f91ea3b101a0e62521077ddab4", "title": "Adagio Therapeutics | Investor Conference Presentation Deck | 14 slides", "subtitle": "Adagio Therapeutics · 2023-03", "author": "Adagio Therapeutics", "date": "2023-03-01 00:00:00", "pageCount": 14, "kind": "conference-presentation", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de515-1bf5-75fc-a19f-ef7a3323e229", "slug": "a43786f91ea3b101a0e62521077ddab4", "title": "Adagio Therapeutics | Investor Conference Presentation Deck | 14 slides", "rawTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 14 slides", "authorId": "adagio-therapeutics", "authorName": "Adagio Therapeutics", "authorDisplay": "Adagio Therapeutics", "kind": { "slug": "conference-presentation", "label": "Conference presentation" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-03__adagio-therapeutics__investor-conf__a43786f9.pdf", "sourceUrl": "https://www.slidebook.io/company/adagio-therapeutics/presentation/a43786f91ea3b101a0e62521077ddab4/", "sourceDate": "2023-03-06 00:00:00", "presentationDate": "2023-03-01 00:00:00", "ingestedAt": "2026-05-01 19:47:39.214885+00", "status": "ready", "pageCount": 14, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": null, "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-03__adagio-therapeutics__investor-conf__a43786f9", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Conference Presentation Deck", "deck_type_slug": "investor-conference", "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 14, "pagesIndexed": 14, "pagesWithImages": 14, "pagesWithMetadata": 14, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 70, "chartCount": 0, "metricSlides": 0, "toolMatches": 4, "documentToolMatches": 0, "frameworkMatches": 0, "arcMatches": 1, "beatMatches": 3, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "evidence": "The deck follows a clear problem statement (COVID-19 impact), agitation of the problem (limitations of current treatments), and proposed solution (Invivyd platform).", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:06:27.808267+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 4, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 4, "name": "Problem Identification", "beatId": "288e8599-a6b1-4102-93ca-9e91cdaafd9c", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "Slide 4 states 'COVID IS THIRD LEADING CAUSE OF DEATH IN THE U.S.'", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 5, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 4, "name": "Agitation", "beatId": "ccab2ada-1cc8-4c81-9cde-c0f1b2528cce", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4 and 5 agitate the problem by highlighting the need for better solutions.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "d3def03c-312d-4999-8437-44a76f4d6117", "evidence": "The loop is used to emphasize the need for better COVID-19 treatments.", "position": 0, "objective": "Highlight the cost of not acting or current limitations", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:06:27.963721+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "4523cdba-8a0a-456c-9aa4-c98dd9fc0ad9", "evidence": "TD Cowen 43rd Annual Health Care Conference", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 01:41:46.430453+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3de801da-5bdf-4c11-97ed-d3fb27d3c6d5", "evidence": "The slide uses a list/bullet format to present key points about the vulnerability of immunocompromised people and the undervaccinated population.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 01:41:34.060304+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "5a4203f3-4753-4981-9ddb-0819dd030f5b", "evidence": "The slide presents a clear problem statement about COVID-19 being the third leading cause of death in the U.S., highlighting the unmet medical need.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 01:41:34.023636+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "88092956-1252-40e1-bd7e-1e82d4342762", "evidence": "The slide illustrates a process flow for INVIVYD's approach to selecting next-generation COVID-19 product candidates, involving mining human antibody repertoires and predicting viral evolution.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 01:41:34.16759+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/U7-SP9GlrFHFpBIFbE3TAqXGNHiFX5nsYoK6HVXmML0/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNDM3ODZmOTFlYTNiMTAxYTBlNjI1MjEwNzdkZGFiNC9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 11, "componentCount": 3, "textChars": 63, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:01:59.135+00", "seconds": 4.049, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/1", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-1", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.027777777777777776, "w": 0.10694444444444445, "x": 0.8402777777777778, "y": 0.046296296296296294 }, "kind": "image", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:01:59.135+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "745fde17-4d18-48e3-9572-331ef42a3af1", "parentComponentId": null }, { "bbox": { "h": 0.037037037037037035, "w": 0.20694444444444443, "x": 0.049305555555555554, "y": 0.5462962962962963 }, "kind": "paragraph", "text": "March 6, 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:01:59.135+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7c6c37b8-90bb-40fb-89c4-adab0080afae", "parentComponentId": null }, { "bbox": { "h": 0.19074074074074074, "w": 0.6472222222222223, "x": 0.049305555555555554, "y": 0.3888888888888889 }, "kind": "title", "text": "TD Cowen 43rd Annual Health Care Conference", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:01:59.135+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eefc985a-8508-447c-a5b4-eabefc9cd12b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "4523cdba-8a0a-456c-9aa4-c98dd9fc0ad9", "evidence": "TD Cowen 43rd Annual Health Care Conference", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 01:41:46.430453+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/-a_j0vdhgrgGYS7JPe76YRLhSFxbM2fR4d2AYPX3SUY/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNDM3ODZmOTFlYTNiMTAxYTBlNjI1MjEwNzdkZGFiNC9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/Zkj5_iJZrF7dxrDg6qiOWwaTVtE5sD_CgHyWoteAc4c/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNDM3ODZmOTFlYTNiMTAxYTBlNjI1MjEwNzdkZGFiNC9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/WY-34kr2Q-HdVPCzd4l44MS1fiZrVL4k1h9WXf7GfiM/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNDM3ODZmOTFlYTNiMTAxYTBlNjI1MjEwNzdkZGFiNC9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "front_matter", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 6141, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:02.27+00", "seconds": 7.072, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/2", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-2", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.689, "w": 0.932, "x": 0.034, "y": 0.201 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"could,\" \"intend,\" \"target,\" \"project,\" \"estimate,\" \"believe,\" \"predict,\" \"potential\" or \"continue\" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, our belief that our existing cash resources will be sufficient to fund our operations into the second quarter of 2024; the future of the COVID-19 landscape including the expectation of continued evolution and emergence of new variants and subvariants; our ongoing research and clinical development plans; the timing, progress and results of our preclinical studies and clinical trials of our product candidates; the initiation, modification and completion of studies or trials and related preparatory work; the period during which the results of our clinical trials and other studies and research activities will become available, and our research and development programs; our ability to identify novel antibodies designed to address the evolving SARS-CoV-2 threat; our ability to obtain and maintain regulatory approvals for our product candidates; our expectations regarding the size of the patient populations, market acceptance and opportunity for and clinical utility of our product candidates, if approved for commercial use; our expectations regarding the scope of any approved indication for our product candidates; our ability to successfully commercialize our product candidates, including for a new drug category; our ability to leverage our platform to identify and develop future product candidates in additional areas of need; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; our ability to successfully execute on the components of our vision to create the \"perpetual machine\"; the anticipation of ongoing discussions with health authorities; the potential for an emergency use authorization in the U.S. or other regulatory approval; our preclinical activity, plans, technology and resources to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza, in the U.S. and globally; our belief in the potential to discover and develop pipeline candidates as potent and durable antibodies or combination of antibodies for COVID-19; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business and those of our collaborators, our clinical trials and our financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of our product candidates or combination of candidates based on neutralizing activity in pre-clinical studies; variability of results in models used to predict activity against SARS-CoV-2 variants of concern; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process, including the outcome of our discussions with regulatory authorities concerning our clinical trials; whether we are able to successfully monitor, analyze, engineer and optimize new product candidates; whether we are able to create a flow of product candidates that address virus evolution; whether our product candidates or combination of candidates are able to demonstrate activity against predominant SARS-CoV-2 variant(s) in the U.S. and globally; whether we are able to successfully submit an emergency use authorization in the future, and the outcome of any such emergency use authorization submission; whether research and development efforts will improve efficacy of our product candidates against predominant variants or identify additional monoclonal antibodies or combination of antibodies for the prevention and treatment of COVID-19 and other infectious diseases; whether research and development efforts will identify and result in safe and effective therapeutic or preventative options for other infectious diseases in the U.S. or globally and whether we have adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading \"Risk Factors\" in our most recent Annual Report on Form 10-K and our most recent Quarterly Report on Form 10-Q, each filed with the Securities and Exchange Commission (the \"SEC\"), and in our other filings with the SEC, and in our future reports to be filed with the SEC and available at www.sec.gov. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this presentation are made as of this date, and we undertake no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.27+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "89dd72c9-cbc7-4ec6-8d38-d4a4961ea14d", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.409, "x": 0.034, "y": 0.906 }, "kind": "source-note", "text": "© 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc.\nAll trademarks in this presentation are the property of their respective owners.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.27+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9f8867d-5740-49ab-9527-a39cd08d7749", "parentComponentId": null }, { "bbox": { "h": 0.01, "w": 0.007, "x": 0.954, "y": 0.954 }, "kind": "source-note", "text": "2", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.27+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa826488-cb55-427f-be1d-f0c255c0c93b", "parentComponentId": null }, { "bbox": { "h": 0.028, "w": 0.419, "x": 0.039, "y": 0.135 }, "kind": "title", "text": "FORWARD LOOKING STATEMENTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.27+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "659468f2-563c-4b3d-b390-040b0e580fc8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "appendix", "function": "establish_context", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "balanced", "densityScore": 34, "componentCount": 4, "textChars": 274, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:01:59.7+00", "seconds": 3.598, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/3", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-3", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.999, "w": 0.501, "x": 0.499, "y": 0.001 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:01:59.7+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c95df0d6-8a44-4a54-be60-c4ff8c17c97c", "parentComponentId": null }, { "bbox": { "h": 0.156, "w": 0.249, "x": 0.042, "y": 0.574 }, "kind": "paragraph", "text": "Our purpose is to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:01:59.7+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9749a99-0b13-4fc7-a671-7e60213d775e", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.22, "x": 0.042, "y": 0.389 }, "kind": "title", "text": "Providing Hope for Vulnerable People Against Viral Diseases", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:01:59.7+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb47049c-84a6-4a31-a1a1-76c861eb7f4c", "parentComponentId": null }, { "bbox": { "h": 0.079, "w": 0.186, "x": 0.042, "y": 0.244 }, "kind": "title", "text": "OUR VISION & PURPOSE", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:01:59.7+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f952ffe-f4a1-456c-beda-2d964e11bece", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "tension", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 94, "componentCount": 12, "textChars": 2018, "nDataPoints": 6, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:03.989+00", "seconds": 7.859, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/4", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-4", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.22, "w": 0.21, "x": 0.28, "y": 0.3 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6b71ede4-6477-4c71-8dad-ab9b14a4b9c4", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.21, "x": 0.05, "y": 0.3 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12e8ef55-aa7e-489e-9144-b208ef50c253", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.21, "x": 0.51, "y": 0.3 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "14e143b9-0dbc-456f-82d0-3cff1baa4c88", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.21, "x": 0.74, "y": 0.3 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "db4e35ad-4063-4bc6-906a-55a25733a9d2", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.19, "x": 0.3, "y": 0.56 }, "kind": "list", "text": "No vaccine alternatives for prevention\nThere are no monoclonal antibodies authorized or approved for COVID-19 prevention or treatment in U.S. against circulating variants 4,5", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3a2f5dba-8db3-4229-a087-0904e0417c23", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.19, "x": 0.76, "y": 0.56 }, "kind": "list", "text": "Undervaccinated population\nAs of January 31, 2023, ~60% of population in the U.S. aged 65+ have not received the updated bivalent booster8", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "73b05507-062b-4749-ba42-aab5b9c6aab4", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.07, "y": 0.56 }, "kind": "list", "text": "Immunocompromised people are vulnerable to infection\nCDC estimates ~2.7% of U.S. population may be immunocompromised, approximately 8 million people 2,3", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb7949f7-953e-4f9d-8694-ea8e91463b2f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.19, "x": 0.53, "y": 0.56 }, "kind": "list", "text": "People at higher risk of hospitalization and death\n~56 million people in U.S. aged 65+6\n116 million adults in U.S. with comorbidities7", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d242c11a-22e9-4d6c-af1b-780a872cda70", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.92, "x": 0.04, "y": 0.21 }, "kind": "paragraph", "text": "Vaccination and increased levels of population immunity have reduced SARS-CoV-2 associated diseases and mortality; however, significant unmet medical need remains", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d495c97-1a9f-4cf5-b907-335ee3f8b4a5", "parentComponentId": null }, { "bbox": { "h": 0.01, "w": 0.59, "x": 0.05, "y": 0.97 }, "kind": "source-note", "text": "VYD222 is an investigational product candidate not approved for use in any country. The safety and efficacy of VYD222 have not been established.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68416ca8-41ed-49e9-bbbe-3e11611bccea", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.87, "x": 0.05, "y": 0.81 }, "kind": "source-note", "text": "1. https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-leading-cause-of-death-ranking/\n2. Harpaz R, et al. Prevalence of Immunosuppression Among US Adults, 2013. JAMA. 2016;316(23):2547-2548.\n3. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html\n4. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region#:-:text=FDA%20Announces%20Bebtelovimab%20is%20Not%20Currently%20Authorized%20in%20Any%20US%20Region,-Share&text=%5B11%2F30%2F2022%5D,to%20neutralize%20Omicron%20subvariants%20BQ.\n5. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us#:-:text=Based%20on%20this%20revision%2C%20Evusheld,SARS%2DCoV%2D2%20variants.\n6. www.census.gov 1/31/2023\n7. www.census.gov 1/31/23 and https://wwwnc.cdc.gov/eid/article/26/8/20-0679_article\n8. https://www.cnn.com/2022/12/16/health/bivalent-boosters-vaccine-effectiveness-studies/index.html", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c7125012-c5ac-447b-b7bf-47d7909f7715", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.44, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "COVID IS THIRD LEADING CAUSE OF DEATH IN THE U.S.1", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.989+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6aa2a2c6-49d7-4bb4-862d-924f3fd2567b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3de801da-5bdf-4c11-97ed-d3fb27d3c6d5", "evidence": "The slide uses a list/bullet format to present key points about the vulnerability of immunocompromised people and the undervaccinated population.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 01:41:34.060304+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "5a4203f3-4753-4981-9ddb-0819dd030f5b", "evidence": "The slide presents a clear problem statement about COVID-19 being the third leading cause of death in the U.S., highlighting the unmet medical need.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 01:41:34.023636+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 4, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 4, "name": "Problem Identification", "beatId": "288e8599-a6b1-4102-93ca-9e91cdaafd9c", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "Slide 4 states 'COVID IS THIRD LEADING CAUSE OF DEATH IN THE U.S.'", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 5, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 4, "name": "Agitation", "beatId": "ccab2ada-1cc8-4c81-9cde-c0f1b2528cce", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4 and 5 agitate the problem by highlighting the need for better solutions.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "d3def03c-312d-4999-8437-44a76f4d6117", "evidence": "The loop is used to emphasize the need for better COVID-19 treatments.", "position": 0, "objective": "Highlight the cost of not acting or current limitations", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:06:27.963721+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "setup", "function": "propose_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "propose_solution", "functionCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-185b-74e9-bdfd-ea8cf318563f", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 827, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:00.731+00", "seconds": 3.968, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/5", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-5", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.289, "w": 0.19, "x": 0.716, "y": 0.416 }, "kind": "list", "text": "Growing number of antibodies aiming to overcome SARS-CoV-2 viral evolution\nPlans to expand into other respiratory viruses with ongoing discovery campaigns in influenza", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:00.731+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "059c3e67-79f6-44a0-8957-b341b755cdd9", "parentComponentId": null }, { "bbox": { "h": 0.289, "w": 0.19, "x": 0.29, "y": 0.416 }, "kind": "list", "text": "Rapid repeated antibody isolation, engineering, and predictive modeling of viral evolution\nCandidate optimization for potency, half-life, potential to resist escape, and ease of manufacture", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:00.731+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ac25025-3218-4b95-a534-f6eb7d59fe65", "parentComponentId": null }, { "bbox": { "h": 0.46, "w": 0.19, "x": 0.503, "y": 0.416 }, "kind": "list", "text": "VYD222: a monoclonal antibody for prevention or treatment of COVID-19\nEngineered from adintrevimab (ADG20), which has robust safety data package\nPhase 1 clinical trial start planned for Q1 2023\nVYD224, Candidate 3, Candidate 4: additional monoclonal antibodies for prevention or treatment of COVID-19", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:00.731+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80a0211a-e8c8-4a39-a115-3b839d127260", "parentComponentId": null }, { "bbox": { "h": 0.21, "w": 0.189, "x": 0.077, "y": 0.416 }, "kind": "list", "text": "Antibodies designed to protect humanity from serious viral diseases\nContinuous innovation to address COVID-19 variants of concern", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:00.731+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e122ee07-d45c-41e8-8f89-c694bc55a47f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.622, "x": 0.045, "y": 0.13 }, "kind": "title", "text": "INVIVYD: A PLATFORM APPROACH TO INNOVATION", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:00.731+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "34528949-6c0a-4c95-856c-1b63f08bf692", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 4, "name": "Agitation", "beatId": "ccab2ada-1cc8-4c81-9cde-c0f1b2528cce", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4 and 5 agitate the problem by highlighting the need for better solutions.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "d3def03c-312d-4999-8437-44a76f4d6117", "evidence": "The loop is used to emphasize the need for better COVID-19 treatments.", "position": 0, "objective": "Highlight the cost of not acting or current limitations", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:06:27.963721+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "setup", "function": "propose_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "propose_solution", "functionCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-185b-74e9-bdfd-ea8cf318563f", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 5, "textChars": 798, "nDataPoints": 1, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:02.662+00", "seconds": 4.683, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/6", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-6", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.63, "w": 0.39, "x": 0.52, "y": 0.29 }, "kind": "diagram", "text": "~10 million B Cells\nRBD Binders\nNeutralizers\nNon-Convergent Clones\nHigh Potency\nBroad VOC Binders\nLow Escape Risk\nMultiple Candidates\nEngineer", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "funnel", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.662+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "356c3b61-f0cd-4058-90c5-3ae33d32be16", "parentComponentId": null }, { "bbox": { "h": 0.58, "w": 0.43, "x": 0.045, "y": 0.32 }, "kind": "list", "text": "MINE: Mine human antibody repertoires induced following contemporary SARS-CoV-2 exposures\nPREDICT: Monitor variants continuously, pinpoint dominant spike protein sites targeted by human antibody repertoires, and map common mutational escape routes to predict future variants\nIDENTIFY: Identify potent mAb candidates that target rare epitopes not under strong immune pressure\nOPTIMIZE: Engineer to optimize candidate properties", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.662+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b99082e0-0471-46eb-a1ce-364c08a1c6cc", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.07, "x": 0.86, "y": 0.16 }, "kind": "source-note", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.662+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ec5f26d-0d21-4760-b852-a5c7f4819756", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.89, "x": 0.045, "y": 0.23 }, "kind": "title", "text": "Continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.662+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12670943-f20e-4ba7-8828-27b13ca80a9a", "parentComponentId": null }, { "bbox": { "h": 0.105, "w": 0.89, "x": 0.045, "y": 0.07 }, "kind": "title", "text": "INVIVYD IN ACTION: APPROACH TO SELECTION OF NEXT GENERATION COVID-19 PRODUCT CANDIDATES", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.662+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "edc52f4b-fae4-4ade-9518-fa6a316d14c1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "88092956-1252-40e1-bd7e-1e82d4342762", "evidence": "The slide illustrates a process flow for INVIVYD's approach to selecting next-generation COVID-19 product candidates, involving mining human antibody repertoires and predicting viral evolution.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 01:41:34.16759+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "setup", "function": "propose_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "propose_solution", "functionCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-185b-74e9-bdfd-ea8cf318563f", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 5, "textChars": 581, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:03.288+00", "seconds": 4.827, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/7", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-7", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.52, "w": 0.39, "x": 0.54, "y": 0.28 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.288+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ffa9b139-985d-4b31-90cf-5f6c810a0533", "parentComponentId": null }, { "bbox": { "h": 0.41, "w": 0.44, "x": 0.045, "y": 0.258 }, "kind": "list", "text": "VYD222 (Engineered from adintrevimab)\nDesigned for:\n• High potency\n• Lack of polyreactivity\n• Long half-life\n• Developability\n• Potential to resist escape\n• Target non-overlapping epitopes of spike RBD\n• Rare epitopes under less immune pressure\n• Conserved across human ACE2-using sarbecoviruses", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.288+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da35c4b8-6d84-48c0-a83b-de0d36342728", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.59, "x": 0.045, "y": 0.728 }, "kind": "paragraph", "text": "VYD222 mAb candidate has demonstrated in vitro neutralizing activity against dominant variants of concern, including Omicron sub-lineages up to and through XBB.1.5", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.288+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12e964f8-3b48-4c9b-a654-ba73b084bc7c", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.16, "x": 0.045, "y": 0.915 }, "kind": "source-note", "text": "RBD, receptor binding domain\nVOC, variant of concern", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.288+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe0ab81c-f2b7-43d4-bf4b-10644372a747", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.88, "x": 0.045, "y": 0.045 }, "kind": "title", "text": "SHOWCASE OF VYD222: ENGINEERED FOR BROAD ACTIVITY AND PROLONGED UTILITY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.288+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f730d8d-c998-4702-a899-2f8e852f3b3d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "setup", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 5, "textChars": 845, "nDataPoints": 30, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:03.702+00", "seconds": 4.954, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/8", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-8", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.106, "w": 0.209, "x": 0.694, "y": 0.864 }, "kind": "list", "text": "✓ Neutralizing in standardized in vitro assays\nX Not neutralizing in standardized in vitro assays\n- Data Not Available\nCurrent Circulating Variants", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.702+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9a88815-e83f-49cd-ba42-35fadbcf7531", "parentComponentId": null }, { "bbox": { "h": 0.036, "w": 0.547, "x": 0.045, "y": 0.935 }, "kind": "paragraph", "text": "As of January 2023, there are no authorized or approved COVID-19 mAbs on the market in the U.S.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.702+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "188d9a39-d640-47a1-b256-d0e480bde323", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.57, "x": 0.045, "y": 0.864 }, "kind": "source-note", "text": "Neutralization data from published studies or measured by Invivyd using public sequences. Data current as of March 3, 2023. VYD222 data generated by Labcorp-Monogram Biosciences using the pseudovirus PhenoSense® SARS-CoV-2 Neutralizing Antibody Assay.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.702+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63e03f22-7af9-4fdc-8238-4a704144f5dd", "parentComponentId": null }, { "bbox": { "h": 0.619, "w": 0.91, "x": 0.045, "y": 0.212 }, "kind": "table", "text": "VARIANT, SUBLINEAGE, VYD222, EVUSHELD®*, BEBTELOVIMAB*\nWT(D614G), WT(D614G), ✓, ✓, ✓\nDelta, B.1.617.2, ✓, ✓, ✓\nOmicron, BA.1, ✓, -, ✓\nBA.4/5, ✓, ✓, ✓\nBA.4.6, ✓, X, ✓\nBF.7, ✓, -, -\nBQ.1.1, ✓, X, X\nBA.2.75, ✓, -, ✓\nXBB.1, ✓, X, X\nXBB.1.5, ✓, X, X", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.702+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d679da82-a793-439a-b921-117f632c1968", "parentComponentId": null }, { "bbox": { "h": 0.087, "w": 0.73, "x": 0.045, "y": 0.086 }, "kind": "title", "text": "VYD222 DEMONSTRATED BROAD IN VITRO NEUTRALIZING ACTIVITY AGAINST VARIANTS OF CONCERN AND SUB-LINEAGES TESTED", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.702+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bed88882-fbad-4f11-9efe-7040693e55cb", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "resolution", "function": "plan_implementation", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 6, "textChars": 534, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:15.997+00", "seconds": 17.14, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/9", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-9", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.9, "x": 0.05, "y": 0.39 }, "kind": "diagram", "text": "Late Q4 2020: Adintrevimab IND Enabling & Submission; 1H 2021: Phase 1 First in Human 1st Subject Dosed, EVADE (prevention) Ph2/3 Enrollment Initiated (US); 2H 2021: STAMP (treatment) Ph2/3 Enrollment Initiated (ex-US); Q1 2022: Adintrevimab Topline Data", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:15.997+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fde21b91-37af-4a48-8057-9f56f7777bbe", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.54, "y": 0.78 }, "kind": "image", "text": "STAMP", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:15.997+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b93ce5d-34aa-4968-b866-0a3a798db77c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.37, "y": 0.78 }, "kind": "image", "text": "EVADE", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:15.997+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "59f3f9d9-997b-436c-896f-301d9edaa336", "parentComponentId": null }, { "bbox": { "h": 0.01, "w": 0.06, "x": 0.89, "y": 0.16 }, "kind": "image", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:15.997+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8586967-1007-4cc2-9083-355ba9973a50", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.64, "x": 0.045, "y": 0.92 }, "kind": "source-note", "text": "Adintrevimab is an investigational product candidate that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established.", "attrs": { "numbered": true }, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:15.997+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "309d49dc-80ea-43f1-a29f-80c086298f04", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.889, "x": 0.045, "y": 0.08 }, "kind": "title", "text": "DEMONSTRATED DEVELOPMENT SUCCESS AND SPEED WITH ADINTREVIMAB: FROM IND TO TOPLINE DATA IN 16 MONTHS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:15.997+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3a7c515b-b1c7-4b81-a994-1871ed50a9ac", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "setup", "function": "propose_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "propose_solution", "functionCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-185b-74e9-bdfd-ea8cf318563f", "version": 1, "description": null }, "density": "dense", "densityScore": 73, "componentCount": 6, "textChars": 1097, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:03:01.555+00", "seconds": 62.43, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/10", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-10", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.22, "w": 0.344, "x": 0.62, "y": 0.62 }, "kind": "image", "text": "World Health Organization WHO/BS/2023.2442 ENGLISH ONLY WHO Guideline on the nonclinical and clinical evaluation of monoclonal antibodies and related biological products intended for the prevention or treatment of human infectious diseases.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:03:01.555+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12517f3f-66d9-405d-b85b-537a3a819f4b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.369, "x": 0.595, "y": 0.298 }, "kind": "image", "text": "Joint EMA-FDA workshop: Efficacy of monoclonal antibodies in the context of rapidly evolving SARS-CoV-2 variants", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:03:01.555+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4eb2a54c-68f1-48fc-ad9e-e0c2d9c0bd59", "parentComponentId": null }, { "bbox": { "h": 0.17, "w": 0.344, "x": 0.62, "y": 0.398 }, "kind": "image", "text": "ADVISORY COMMITTEE MEETING Vaccines and Related Biological Products Advisory Committee January 26, 2023 Meeting Announcement JANUARY 26, 2023", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:03:01.555+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "713022bd-498a-4113-91d7-695a79212679", "parentComponentId": null }, { "bbox": { "h": 0.38, "w": 0.53, "x": 0.045, "y": 0.27 }, "kind": "list", "text": "Regulators are seeking strategies to streamline development of monoclonal antibodies and vaccines\nThe necessity of streamlined development for new mAb products is supported by the science\nUnderstanding of SARS-CoV-2 biology has grown exponentially\nAccumulating data enables scientists to predict mAb effectiveness based on in vitro data which can then be confirmed in patients\nThis is especially true for products closely related to those previously studied", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:03:01.555+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "44d388f9-c20b-404e-9ae7-41fbc97b9683", "parentComponentId": null }, { "bbox": { "h": 0.027, "w": 0.53, "x": 0.045, "y": 0.72 }, "kind": "title", "text": "Possible Implication: Advance medicines to patients faster", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:03:01.555+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "57ef6d1c-e36e-4e7e-af0a-b004297309a7", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.706, "x": 0.045, "y": 0.08 }, "kind": "title", "text": "REGULATORS CONSIDERING STRATEGIES TO ACCELERATE MONOCLONAL ANTIBODY DEVELOPMENT TIMELINES", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:03:01.555+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4092407e-ec84-4852-99db-1e3d4ccffc35", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "setup", "function": "propose_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "propose_solution", "functionCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-185b-74e9-bdfd-ea8cf318563f", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 3, "textChars": 378, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:02.705+00", "seconds": 3.3, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/11", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-11", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.602, "w": 0.701, "x": 0.149, "y": 0.28 }, "kind": "diagram", "text": "PREDICTION of viral evolution and rational selection of privileged epitopes; Candidate antibody DISCOVERY and ENGINEERING; Efficient clinical DEVELOPMENT for multiple use cases and populations; Flexible and highly efficient MANUFACTURING; COMMERCIAL design for a large drug category, not solely a pandemic emergency", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.705+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1f4ea13-91b8-449f-ba10-8427a6d48e96", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.079, "x": 0.869, "y": 0.14 }, "kind": "image", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.705+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d13680ab-1eb4-41e1-bb5e-c63c22dbe29a", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.69, "x": 0.045, "y": 0.076 }, "kind": "title", "text": "BUILDING ON OUR VISION TO CREATE THE “PERPETUAL MACHINE”", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:02.705+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fdd76af7-6823-4601-b270-ab80df11227d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 28, "componentCount": 3, "textChars": 326, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:03.363+00", "seconds": 3.325, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/12", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-12", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.79, "x": 0.044, "y": 0.95 }, "kind": "source-note", "text": "Investigational therapies are not approved for use by regulatory authorities. The safety and efficacy of pipeline candidates have not been established.", "attrs": {}, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.363+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da190e43-6d4b-4f51-8f9b-5f51f1e7a945", "parentComponentId": null }, { "bbox": { "h": 0.602, "w": 0.913, "x": 0.044, "y": 0.25 }, "kind": "table", "text": "PROGRAMS, PLATFORM, INDICATION(S), DEVELOPMENT STATUS (DISCOVERY, IND-ENABLING, PHASE 1, PHASE 2, PHASE 3), STATUS", "attrs": {}, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.363+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ec47f829-d7b3-4aef-80c5-c1d4b095f9e0", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.739, "x": 0.044, "y": 0.07 }, "kind": "title", "text": "VYD222 IS ONE OF MANY ANTIBODIES IN INVIVYD'S ROBUST\nPIPELINE", "attrs": {}, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:03.363+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9025cb6-0c01-44b1-8f8c-96901ad23328", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "function": "frame_situation", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "frame_situation", "functionCanon": { "name": "Frame situation", "slug": "frame_situation", "status": "active", "canonId": "019de52d-17bc-718f-8752-05ef2b72d7b3", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 6, "textChars": 418, "nDataPoints": 3, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:05.461+00", "seconds": 5.334, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/13", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-13", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 0.016, "w": 0.068, "x": 0.888, "y": 0.169 }, "kind": "image", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:05.461+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a3b08431-2039-434d-8436-b61c9599911e", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.24, "x": 0.69, "y": 0.44 }, "kind": "metric", "text": "Total fully diluted shares of common stock outstanding* as of September 30, 2022: 130.4 million", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:05.461+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "534f4c0f-94f9-424e-a4ce-ff0afc90920f", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.24, "x": 0.079, "y": 0.45 }, "kind": "metric", "text": "Cash Position: Cash, cash equivalents and marketable securities were $419 million as of September 30, 2022", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:05.461+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c84abe4-1b22-4e31-8c46-151f17eed0f7", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.179, "x": 0.399, "y": 0.496 }, "kind": "metric", "text": "Planned cash runway into Q2 2024", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:05.461+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c97186a6-8c8a-4b1f-82c6-b5d9ab1cfb11", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.349, "x": 0.045, "y": 0.945 }, "kind": "source-note", "text": "*Includes vested and unvested outstanding options as of September 30, 2022; excludes treasury stock", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:05.461+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "895fd0e2-a039-4b9c-9d71-f4b25e93e986", "parentComponentId": null }, { "bbox": { "h": 0.099, "w": 0.73, "x": 0.045, "y": 0.075 }, "kind": "title", "text": "COMPANY WELL CAPITALIZED TO DEVELOP LEAD CANDIDATE & ADDITIONAL PIPELINE ASSETS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:05.461+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4c6df71-5d82-476b-ba27-b4dce371a4ce", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "setup", "function": "transition", "rawType": "transition", "block": null, "metadata": { "slideType": "transition", "slideTypeCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-0693-7766-9f05-887f41f8e41e", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 3, "textChars": 16, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 09:02:04.499+00", "seconds": 3.317, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/14", "deck": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229", "deckAnchor": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-14", "deckJson": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json" }, "components": [ { "bbox": { "h": 1, "w": 1, "x": 0, "y": 0 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:04.499+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "adc4c7ac-9f29-49a4-8039-08c18b5f836d", "parentComponentId": null }, { "bbox": { "h": 0.022222222, "w": 0.095, "x": 0.8416667, "y": 0.046666667 }, "kind": "image", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:04.499+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "960dea6c-e049-4b65-9088-9e9d29b4d26c", "parentComponentId": null }, { "bbox": { "h": 0.046666667, "w": 0.265, "x": 0.6425, "y": 0.7866667 }, "kind": "title", "text": "THANK YOU", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 09:02:04.499+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d428ee6f-4c72-4bf0-9350-ba0aeae65dbe", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7", "matchId": "76b886e5-1295-4fd6-bfc0-0714ba06fc71", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 5, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0", "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.", "position": 1, "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:06:28.001869+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true } ], "arcBeats": [ { "from": 4, "to": 4, "label": "Problem Identification", "description": "Slide 4 states 'COVID IS THIRD LEADING CAUSE OF DEATH IN THE U.S.'" }, { "from": 4, "to": 5, "label": "Agitation", "description": "Slides 4 and 5 agitate the problem by highlighting the need for better solutions." }, { "from": 5, "to": 14, "label": "Solution", "description": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress." } ], "loops": [ { "from": 4, "to": 5, "label": "Cost Of Inaction", "description": "Highlight the cost of not acting or current limitations" }, { "from": 5, "to": 14, "label": "Jobs To Be Done", "description": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment" } ] }